Experimental infection of the respiratory tract with Mycoplasma pneumoniae. by Hu, P C et al.
Environmental Health Perspectives
Vol. 35, pp. 101-106, 1980
Experimental Infection of the Respiratory
Tract with Mycoplasma pneumoniae
by Ping-Chuan Hu,* Jerome M. Kirtz,*
Donald E. Gardner,* and Dwight A. Powellt
M. pneumoniae, a common human respiratory pathogen, has been studied experimentally for years
using intranasal inoculation ofthe golden Syrian hamster. Because ofrecent evidence outlining the role in
pulmonary immune development ofparticle size and depth ofmycoplasma deposition in the hamster lung,
we developed an aerosol chamber for the reproducible aerosolization of radiolabeled M. pneumoniae.
Organisms were labeled tohighspecificactivitybytheincorporation of3H-oleic acid and aerosolized under
airflow and humidity conditions creating a mean particle diameter of 2.0 ,um. Under these conditions,
viablemycoplasmas werereproducibly andevenlydistributed toallmajorlobesofthelung. Examination of
radioactiveclearance andorganism viability within the lungduringthefirst48 hrafteraerosolization have
suggested a minimal role for macrophage mycoplasmacidal activity and a more prominent role for ciliary
clearance. Data from aerosol infections of hamsters with radio-labeled M. pneumoniae should provide a
uniqueopportunity toexamine inahighlycontrolledmannertheeffectsofairpollutantsontheinitial stages
of infection as well as effects on the development of pulmonary immunity and histologic alterations.
Introduction
Mycoplasma pneumoniae is one ofthe most com-
mon pathogens of the human respiratory tract. In-
fection with this agent is the leading cause of acute
pneumonitis in high contact environments such as
college campuses and military bases, as well as being
a common cause ofrespiratory illness in children (1).
Illnesses associated with M. pneumoniae infections
range from mild upper respiratory infection, through
tracheobronchitis, to acute pneumonia (2). These
agents have been associated with exacerbations of
chronic bronchitis in adults with chronic obstructive
pulmonary disease and with severe illnesses in com-
promised hosts such as patients with B-cell im-
munodeficiency (3) orsickle cell anemia(4). Because
ofthe prevalence and seriousness ofM. pneumoniae
associated respiratory illness, it is important to de-
termine the effects ofair pollution on the interaction
between this organism and host respiratory tissues.
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Fortunately, the Golden Syrian hamster provides an
established animal model for M. pneumoniae infec-
tion(5). The purpose ofthis paperisto reviewbriefly
the features which have made this animal model so
ideal for studying M. pneumoniae pathogenesis, to
describe a recently developed method for studying
this model using aerosolized, radioactively labeled
M. pneumoniae, and finally, to describe some ob-
servations on the deposition and clearance of
aerosolized mycoplasmas within hamster lungs.
Review of Animal Model
Mycoplasma pneumoniae
Infection
Studies on the pathogenesis of M. pneumoniae
infection in the Golden Syrian hamster have been
conducted bothin vitro andin vivo. One main thrust
ofthein vitro work hasinvolved the studyofisolated
tracheal rings infected with M. pneumoniae (6, 7).
Through these studies it has been established that
M. pneumoniae is afilamentous organism, lacking a
cell wall, but possessing a unique tip structure
responsible for its attachment to its primary host
target tissue, ciliated respiratory epithelium (6). This
101attachment causes a variety ofadverse effects on the
ciliated cell including alterations in cellular metabo-
lism (8, 9), changes in cellular ultrastructural mor-
phology (6), and eventually, disorganization of
ciliary activity and loss of cilia from the epithelial
surface (10).
Additionally, examination of the in vitro interac-
tion between M. pneumoniae and isolated alveolar
macrophages (11, 12) has shown that M. pneu-
moniae, like several other mycoplasma species (13),
has the capacity to resist phagocytosis unless op-
sonized with specific antibody or complement. This
feature exists despite the absence of an identifiable
capsule orcellwall, the keycomponentsessentialfor
bacterial antiphagocytic capacity.
Studies ofthe effects ofM. pneumoniae infection
in the Golden Syrian hamsterbegan with the work of
Dajani et al. (5). Following intranasal inoculation of
0.2 ml ofvirulent organisms, the hamster develops a
bronchopneumonia which is very similar to human
disease. At the peak of infection, the histologic pic-
ture consists of scattered areas ofperibronchial and
to a lesser extent perivascular round cell infiltrate.
The intraluminal exudate which develops is com-
posed of mononuclear and polymorphonuclear
phagocytes (14). Pulmonary disease is evident by
day 3 to 7 post infection, peaks on the day 10 to 14,
and begins to resolve by the third week ofinfection.
All animals ultimately recover from the primary in-
fection with a return to normal ofthe lung histology
and complete clearance of the organisms. The de-
velopment of IgG antibodies, as measured by com-
plementfixation and growth inhibition, follow atime
course similar to human disease. Whenanimals have
recoveredfrom aprimary infection,theyare leftwith
a long-lasting relative immunity against reinfection.
While the precise mediators ofthisimmunity remain
undefined, it is known that stimulation of local pul-
monary immune mechanisms is moreimportantthan
stimulation of systemic immunity (15).
This concept was substantiated following the re-
cent article byJemski et al. (16), outlining the role of
aerosol particle size and site of deposition of
M. pneumoniae on the development of respiratory
disease and immunity in hamsters. In their report,
representing the only published accountofananimal
model aerosol infection by M. pneumoniae, the au-
thors demonstrated that the response ofhamsters to
M. pneumoniae infection wasdeterminedbythe site
of deposition of organisms and by the quantity of
organisms introduced directly into the lower re-
spiratory tract. The variables which were studied
included M. pneumoniae delivered as a large parti-
cle aerosol, with a mass median diameter of8 ,m, a
small particle aerosol with a mass median diameter
of2.3 ,mm, or intranasal inoculation of200 ,ul, 20 ul,
or 2 Al of organisms. Only the large volume in-
tranasal inoculum and the small particle aerosol re-
sulted in deposition of mycoplasmas into the lungs.
The other three routs ofinfection colonized only the
upper airways. The most significant disease as mea-
sured by percent of animals with pneumonia and
overall mean pneumonia score, wasfound inanimals
with the large volume intranasal inoculum. Animals
with small volumes but containing the same number
ofmycoplasmas, administered only to the upper air-
way, developed little or no pneumonia. This obser-
vation suggested to these authors that the develop-
mentofdisease inthe hamstermaydepend largelyon
the initial number oforganisms delivered directly to
the lower respiratory tract. Thus, it would seem that
initial deposition and rate oforganism clearance may
be very important determinants ofdisease develop-
ment.
Similarly, the initial location of organism deposi-
tion within the respiratory tract was critical in the
generation ofa protective immune response. In this
segment of the study, all animals were allowed to
recover 4-8 weeks following primary infection and
then challenged with a large volume inoculum of
intranasal organisms. While any route of infection
conferred at least some protection against disease
development, maximal protective immunity was
seen only in those animals given initial exposure
which provided inoculation ofthe lower respiratory
tract - that is either by large volume intranasal
inoculation orby small particle aerosol. Thus, again,
initial deposition and pulmonary clearance would
seem to be crucial events in determining the genera-
tion of protective immunity.
Aerosol Chamber Development
With these data in hand, we decided that the
evaluation of air pollutant effects on disease and
immune response toM. pneumoniae infection in the
hamster must be studied such that the initial deposi-
tion and clearance could reproducibly be evaluated.
To accomplishthis, an aerosol exposure system was
developed in which viable mycoplasmas, tagged
witharadioactive markercould safelyandefficiently
be delivered in an aerosol with a particle mass diam-
eter that would assure deposition deep within the
lower respiratory tract. One of the main criteria
considered in designing the aerosol inhalation
chamber was to be able to have ahigh concentration
of radioactively labeled M. pneumoniae introduced
into the lungs to make deposition and clearance
studies possible. Thus, we designed a chamber of
small volume with a low total air flow rate to
maximize the organism's air concentration during a
25-min exposure period. In Figure 1 is shown a
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pressed air is filtered and passed into rotometers
which control airflow rate into the nebulizer and the
drying column. Air enters this column through two
tangential inlets causing a turbulence which causes
evaporation ofwater from the nebulized aerosol re-
ducingthe particle size. Fromthe dryingcolumn, the
combinedairstreamsenterthecenterofthechamber
and then flow into the two side exposure sections
where inhalation occurs.
Since M. pneumoniae are human pathogens and
were radioactive in many experiments, stringent
safety precautions were taken tofilter all exhaust air
andprovide adequatecontainmentoftheaerosolized
organisms. This was accomplished by housing the
nebulizer, mixing column and exposure chamber,
inside a stainless steel Rochester chamber, and
venting all exhaust air through several HEPA parti-
cle filters. Sampling of the aerosol particle size was
performed with a seven-stage low flow rate cascade
Lovelace impactor.
(
To prepare radioactive-labeled M. pneumoniae
for aerosolization, organisms were grown on the
inner surface of glass bottles, labeled with tritiated
oleic acid, washedextensively to removeunincorpo-
rated radiolabel, and scraped into M199 containing
1% horse serum. During a single run, 4 ml of sus-
pended organisms containing approximately 1010
colony-forming units (CFU) were aerosolized over a
25-min time period at 21°C and 27% RH. Following
this, 4 ml ofsaline were aerosolized foranadditional
25 min to complete the total exposure. To attain the
desired particle size, the nebulizer flow rate and
dilution air flow rate was 5.5 and 11.5 /min, respec-
tively.
In Table 1 is shown the high degree ofparticle size
reproducibility accomplished with this chamber.
Here, results of experiments occurring over a one-
year time period are presented to demonstrate the
consistency ofthe count median aerodynamic diam-
eter. The latter value, reflecting the particle size
reaching the hamster lung is within the size range
)
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FIGURE 1. Schematic diagram ofMycoplasma pneumoniae aerosol inhalation chamber: (1) valve; (2) pressure regulator; (3) silica gel
scrubber; (4) charcoal scrubber; (5) canister HEPA filter; (6) rotameter; (7) pressure gauge; (8) syringe; (9) nebulizer; (10) mixing
column; (11) exposure chamber; (12) impactor; (13) sampling orifice; (14) sampling pump; (15) containment chamber; (16) HEPA
filter; (17) orifice; (18) fume scrubber; (19) exhaust blower; (20) transformer.
103 April 1980Table 1. Size distribution data for M. pneumoniae aerosol
in eight port chamber.
Count median Geometric Mass median
aerodynamic standard aerodynamic
Exposure diameter deviation diameter
date (CMAD) (rg) (MMAD)
08-19-77 1.8 1.5 2.9
10-11-77 1.6 1.4 2.2
10-20-77 1.7 1.4 2.5
10-25-77 1.7 1.4 2.5
12-01-78 1.7 1.5 2.7
01-17-78 1.4 1.4 2.0
01-19-78 1.4 1.5 2.1
01-21-78 1.3 1.4 1.9
08-04-78 1.5 1.4 2.2
08-07-78 1.5 1.4 2.1
08-14-78 1.6 1.4 2.2
08-16-78 1.6 1.4 2.3
Average + SD 1.57 + 0.15 1.42 + 0.05 2.3 ± 0.3
Table 2. Comparison ofMycoplasma pneumoniae concentrations
in nebulizer solution, air sample, and hamster lungs.
Nebulizer Air Average
solution sample hamster
Exposure concentration, concentration, lung content
date cpm/10 ,ul cpm/ml air at lo, cpm/lung
8-19-77 2.5 x 105 15.6 6,241
8-22-77 0.85 x 105 4.4 2,358
8-31-77 2.4 x 105 13.6 6,097
9-08-77 2.8 x 105 32.1 13,135
10-11-77 1.2 x 105 8.9 4,453
10-13-77 1.2 x 105 7.9 4,210
10-20-77 1.2 x 105 2,403
10-25-77 2.2 x 105 13.4 6,138
12-01-77 0.94 x 105 6,807
01-17-78 1.2 x 105 - 5,424
01-19-78 1.0 x 105 12.6 5,661
01-21-78 0.78 x 105 6.9 4,815
08-04-78 3.6 x 105 41.5 15,937
08-07-78 4.5 x 105 39.6 20,283
08-14-78 3.0 x 105 26.7 15,581
08-16-78 3.2 x 105 - 22,010
which would assure deposition within the distal air-
ways of the lower respiratory tract.
The correlation between the radioactive concen-
tration in the nebulizer solution and the radioactive
counts measured within the central aerosol chamber
andfound inthe hamsters' lungs atthe end ofaerosol
exposure is shown in Table 2. As shown by the re-
gression analyses in Table 3, there was greater than
90% correlation between the concentration ofmyco-
plasmas within the chamber air and that found in
hamster lung.
Ofpotentially more importance, however, was the
similarity of deposition for all animals during each
aerosol exposure. Ifany ports were found to provide
variable exposure or exposure consistently above or
below the mean, the value ofthis exposure chamber
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for comparative studies would be questionable. Fig-
ure 2 demonstrates graphically the excellent corre-
lation ofexposure in all eight animals studied in each
of four successive experiments. These data are
tabulated in Table 4 where it can be seen that the
coefficient of variation of the average for the eight
animals in any one experiment varied from 0.14 to
0.19 cpm/mg of dry lung weight.
One important question in an aerosol system such
as this is the extent to which aerosolized organisms
remain viable. To determine how many organisms
were killed by the aerosolization process, the per-
cent of mycoplasmas found to be viable upon depo-
sition in the hamster lung immediately at the end of
aerosol exposure was multiplied by the specific ac-
tivity (CFU/cpm) ofthe initial aerosol suspension to
determine the theoretical number of viable or-
ganisms delivered to the respiratory tract. The CFU
of organisms recovered divided by this theoretical
number revealed the approximate actual survival
rate which averaged 55%.
Deposition and Clearance of
Mycoplasma pneumoniae in the
Hamster Lung
Following the achievement of technical repro-
ducibility in the mycoplasma aerosol chamber,
clearance studies were undertaken in nonimmune
hamsters. In these studies, pulmonary clearance, as
measured by the removal of radioactively tagged
mycoplasmas from the lung was compared with pul-
monary mycoplasmacidal capacity, as measured by
the rate ofdecline ofmycoplasmaviability withinthe
lung. One aim in these studies was to compare the
clearance and viability curves with similar data pub-
lished on animal models infected with aerosolized
bacteria(17, 18). Priorstudies have examinedin vivo
clearance of radioactively labeled bacteria adminis-
tered to animal lungs by aerosol exposures which
provide particles of approximately 2 ,um mass
mediandiameter. Underthese circumstances, depo-
sition occurs primarily at the alveolar level and pro-
Table 3. Regression analysis of data in Table 2:
Y = A + BX, r = correlation coefficient.
X vs. Y A B r2
Nebulizer solution -995 0.0483 0.76
vs. lung content
Nebulizer solution -3.08 1.00 x 10-4 0.84
vs. air concentration
Air concentration 719 431 0.92
vs. lung content
Environmental Health Perspectives3.0 rate of replication was faster than the rate of clear- ance by host defense mechanisms. At 10 days of
2.0 - post-infection, the number of viable mycoplasmas
reached aplateau of 107organisms perlung, and then
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A started to decline by 6 weeks after the infection.
0.8 ~ ~ h' s Histological sections taken from animals 20 days
0.6 - post-infection showed typical pathology including
0.4 0 84-78 extensive peribronchial infiltration.
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8-7-78 * -CPM/mg DRY LUNG Figure 4 shows the clearance rate ofradioactivity,
0 8.16478 X=AVERAGEOFXsFOR8ANIMALS which was found to be significantly more rapid than
0.2
- the decline in mycoplasma viability, most likely due
to the rapid mucociliary clearance of nonattaching,
0.I I, inactivated aerosolized organisms. There was no
1 2 3 4 5 6 7 8 point on the curve at which the percent ofremaining
CHAMBERPORTNUMBER radioactivity was greater than the percent of viable
URE 2. Chamber position vs. normalized deposition of radio- organisms. From thesedata, then, it would seem that
active-labeled Mycoplasma pneumoniae. alveolarmacrophages innonimmune hamstersplaya
vides the capacity to analyze simultaneously physi-
cal removal and viability of the intra-alveolar orga-
nisms.
With most bacteria, the rate oftransport or physi-
cal clearance of radioisotope out of the lung occurs
more slowly than the decline in the number ofviable
bacteria. This has led to the theory that physical
removal of bacteria plays a relatively minor role in
the early defense ofthe lung and that a more impor-
tant pulmonary defense mechanism involves alveo-
lar macrophage engulfment and intracellular killing
of the inhaled bacteria (19).
Table 4. Specific activity of radioactive-labeled
Mycoplasma pneumoniae deposited in hamster lungs.
Average Standard
Average cpm/mg deviation of
cpm dry lung individual, Coefficient
Exposure for 8 for 8 cpm/mg dry of
date animals animals lung variation
8-04-78 15,937 122.5 19.8 0.16
8-07-78 20,283 166.9 32.0 0.19
8-14-78 15,581 119.0 22.6 0.19
8-16-78 22,010 162.4 22.2 0.14
Figure 3 shows the viability of M. pneumoniae
deposited in the total lung tissue. There was little
decline in the viability ofM. pneumoniae during the
first 8 hr after aerosolization. Only after this time
period was there a decline in viability, such that by
24 hr, the viable micoplasmas in the lung were re-
duced by 90%. Thus, during the initial 8 hr, when
macrophage engulfment and intracellularkillingplay
the chief role in intrapulmonary removal of inhaled
bacteria, little change in M. pneumoniae viability
was noted. However, the number of viable or-
ganisms began to increase significantly by 48 hr fol-
lowing the initial infection, which indicates that the
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FIGURE 3. Clearance of viable Mycoplasma pneumoniae from
hamster lungs following aerosol infection.
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acid-labeled Mycoplasma pneumoniae.
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105limited role in the early pulmonary clearance of
aerosolized M. pneumoniae and the interaction of
M. pneumoniae and alveolar macrophages noted
fromin vitro studies are mostlikely representative of
the relationship occurring in vivo (11). On the other
hand, the role ofmucociliary clearance would seem
to be a more important nonspecific host defense
mechanism inminimizingtheinitial numberofviable
organisms capable of establishing residence within
the host lung tissues.
With the establishment of this technique for the
reproducible aerosolization of viable, radiolabeled
M. pneumoniae we are encouraged that many fea-
tures of this important respiratory infection can be
examined in the hamster animal model and the ad-
verse effects ofairpollution exposuredetermined. In
addition to the ready measurement ofdeposition and
clearance with this system, we have demonstrated
that aerosol infected hamsters eventually develop
histologic changes and serologic responses compar-
able to animals infected by 0.2 ml intranasal inocu-
lation. Thus, airpollutant effects onthedevelopment
ofthis form ofchronic pneumonia, as well as on the
generation of a protective immune response, will
also be among our future research objectives.
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